DNA REPAIR DRUGS MARKET ANALYSIS

DNA Repair Drugs Market, By Drug Type (Niraparib, Olaparib, Rucaparib, Talazoparib), By Application (Ovarian Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Peritoneal Cancer, Others), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

In June 2024, Merck provided updates on its oncology pipeline, emphasizing its focused approach to developing potential new medicines for cancer patients. Highlights include plans to initiate multiple Phase Ib and II clinical studies this year for tuvusertib and M9466, both DNA damage response inhibitors. Additionally, Merck has advanced its lead antibody-drug conjugate (ADC), M9140, to Phase Ib following promising clinical results and intends to explore its application in additional cancer types.
In December 2022, the European Union sanctioned the use of AstraZeneca and MSD's Lynparza (olaparib) alongside abiraterone and prednisone or prednisolone for treating metastatic castration-resistant prostate cancer (mCRPC) in adult males who are ineligible for chemotherapy.
In April 2022, Janssen Pharmaceutical submitted an application to the European Medicines Agency (EMA) seeking approval for niraparib in combination with abiraterone acetate, formulated as a dual-action tablet (DAT), along with prednisolone, for the treatment of patients with prostate cancer who have progressed to metastatic castration-resistant prostate cancer (mCRPC).